골수증식 종양의 2017년 WHO 진단기준 주요 변경 사항의 이해Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms
- Other Titles
- Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms
- Authors
- 장미애
- Issue Date
- 2018
- Publisher
- 대한내과학회
- Keywords
- Essential thrombocythemia; Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis; World Health Organization; 본태혈소판증가증; 골수증식 종양; 진성적혈구증가증; 일차골수섬유증; 세계보건기구
- Citation
- 대한내과학회지, v.93, no.4, pp.351 - 359
- Journal Title
- 대한내과학회지
- Volume
- 93
- Number
- 4
- Start Page
- 351
- End Page
- 359
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6574
- ISSN
- 1738-9364
- Abstract
- The World Health Organization (WHO) Classification of Tumors of Haematopoietic and Lymphoid Tissues was recently published in a revised fourth edition. The categories of myeloproliferative neoplasms (MPNs) have not significantly changed since the 2008 fourth edition of the classification; however, newly discovered mutations including CALR and CSF3R and improved characterizations and standardizations of morphological features of some entities, particularly BCR-ABL1-negative MPNs, have impacted the diagnostic criteria of disease entities, increasing the reliability and reproducibility of diagnoses. The 2017 revised edition attempts to incorporate new clinical, prognostic, morphologic, and genetic data that have emerged since the last edition. This article reviews the major changes in the classification and their rationale for MPN classification within the revised 2017 WHO system.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Clinical Pathology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.